Insider Spends US$3.0m Buying More Shares In Inari Medical
Insider Spends US$3.0m Buying More Shares In Inari Medical
Those following along with Inari Medical, Inc. (NASDAQ:NARI) will no doubt be intrigued by the recent purchase of shares by Donald Milder, Independent Chair of the Board of the company, who spent a stonking US$3.0m on stock at an average price of US$53.44. There's no denying a buy of that magnitude suggests conviction in a brighter future, although we do note that proportionally it only increased their holding by 1.7%.
毫无疑问,跟随Inari Medical, Inc.(纳斯达克股票代码:NARI)的人会对该公司董事会独立主席唐纳德·米尔德最近收购股票感兴趣,他在股票上花费了惊人的300万美元,平均价格为53.44美元。不可否认,如此大规模的买入表明他们对更光明的未来充满信心,尽管我们确实注意到,按比例计算,这只会使他们的持股量增加了1.7%。
View our latest analysis for Inari Medical
查看我们对 Inari Medical 的最新分析
Inari Medical Insider Transactions Over The Last Year
去年的Inari Medical内幕交易
In the last twelve months, the biggest single sale by an insider was when the Director, William Hoffman, sold US$5.7m worth of shares at a price of US$70.87 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$53.27. So it may not tell us anything about how insiders feel about the current share price.
在过去的十二个月中,内部人士最大的一次出售是董事威廉·霍夫曼以每股70.87美元的价格出售了价值570万美元的股票。虽然我们通常不喜欢看到内幕销售,但更令人担忧的是是否以较低的价格进行销售。令人欣慰的是,此次出售的价格远高于当前的股价,即53.27美元。因此,它可能无法告诉我们内部人士对当前股价的看法。
All up, insiders sold more shares in Inari Medical than they bought, over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
总而言之,去年业内人士出售的Inari Medical股票多于他们购买的股份。您可以在下表中看到过去一年的内幕交易(由公司和个人进行的)。点击下图,你可以看到每笔内幕交易的确切细节!
I will like Inari Medical better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我看到一些重大的内幕收购,我会更喜欢Inari Medical。在我们等待的同时,请查看这份免费清单,列出了最近有大量内幕收购的成长型公司。
Does Inari Medical Boast High Insider Ownership?
Inari Medical 是否拥有很高的内部所有权?
For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Inari Medical insiders own 9.9% of the company, currently worth about US$308m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
对于普通股股东来说,值得检查一下公司内部人士持有多少股票。我们通常希望看到相当高的内部所有权水平。稻荷医疗内部人士拥有该公司9.9%的股份,根据最近的股价,目前价值约3.08亿美元。大多数股东会很高兴看到这种内部所有权,因为这表明管理层的激励措施与其他股东非常一致。
So What Do The Inari Medical Insider Transactions Indicate?
那么,Inari Medical Insider 交易表明了什么?
Unfortunately, there has been more insider selling of Inari Medical stock, than buying, in the last three months. And our longer term analysis of insider transactions didn't bring confidence, either. It is good to see high insider ownership, but the insider selling leaves us cautious. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Every company has risks, and we've spotted 2 warning signs for Inari Medical you should know about.
不幸的是,在过去的三个月中,Inari Medical股票的内幕抛售多于买入的股票。而且,我们对内幕交易的长期分析也没有带来信心。看到较高的内部所有权是件好事,但内幕抛售使我们持谨慎态度。虽然我们喜欢了解内部人士的所有权和交易情况,但在做出任何投资决策之前,我们一定要考虑股票面临的风险。每家公司都有风险,我们发现了两个你应该知道的Inari Medical警告信号。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你想看看另一家公司——一家财务状况可能优越的公司——那么千万不要错过这份免费的股本回报率高、债务低的有趣公司的名单。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。